A novel mRNA cancer vaccine helps reduce the chances of melanoma patients’ tumors returning
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.
This page is Both News's AI analysis of the article, not the article itself. Read the full story on the publisher's site.
Read the original articleThe Washington Times · washingtontimes.comRead Just the Facts3 outlets, left to rightOur verdict
Political lean
0 = center. The further from 0, the stronger the lean (max 10).
Reporting balance
How complete and even-handed the reporting is — separate from which side it leans.
This AP wire story on a personalised mRNA melanoma vaccine has a centre lean and a measured headline, and it attributes its main claim to the Moderna and Merck study. Its main weakness is that it gives a single enthusiastic expert voice and a relative risk figure (42%) with no absolute numbers, trial size, safety data or independent comment. Readers should treat the result as company-released, promising but unverified in the visible text, and look for independent analysis before drawing firm conclusions.
- Why this lean
- The story has no left-right angle. It is a health and science report on a clinical study. Its tone is positive about the vaccine, but that is a science-news framing rather than a partisan one. Its language is plain and attributed, and it contains no political labels or partisan sources.
- Framing
- The story treats the mRNA cancer vaccine as a notable medical advance and presents the Moderna and Merck study results as its central news.
Confidence: Medium — The supplied text is truncated partway through the article body, so the later sections (possible cautions, safety data, further expert comment or the drugmakers' own statements) may not be visible. The assessment is based only on the visible lede and early paragraphs.
Key Findings
- 1The main finding is attributed to its source: 'according to results of a major study released Thursday by drugmakers Moderna and Merck.' This tells readers who produced the results, which is good practice, but the piece does not add any independent check of them in the visible text.
- 2The only evaluative voice is one physician: 'The field has been looking for a win and I think this one is a big one.' The quote is clearly attributed to Dr. Tawbi, but with no sceptical or independent expert alongside him, the story's positive tone rests on a single source.
- 3The key number is a relative figure: 'reduced by 42% the risk of melanoma returning two years after surgery.' Without the absolute risk in each group, the figure is hard to interpret, and the visible text does not say how large the trial was.
- 4The headline is measured and consistent with the body: 'helps reduce the chances' matches the lede's description of a reduction in recurrence risk, so the headline does not overclaim.
- 5Strengths: the lede is plain and attributed, the expert is named with an institution, and the story avoids sensational terms. Weaknesses: it lacks trial details, independent comment, safety information and any note on whether the results are peer reviewed.
Who gets a voice
- Dr. Hussein Tawbi, MD Anderson Cancer CenterTreating physician and the only quoted expert in the visible textClinical enthusiasm for the resultMain voice
- Moderna and MerckDrugmakers that released the study resultsIndustry and study sponsorsMinor voice
Loaded language
The adjective 'major' asserts importance before readers have any information about the trial's size or design, which echoes the sponsors' promotional framing.
'Significantly' can be read as a claim of statistical significance, yet the visible text gives no p-value or confidence interval, so the word implies more certainty than the text supports.
The phrase is a superlative that presents the product as unprecedented without any comparison to other approaches.
'Brewed' is a casual word that makes manufacturing sound informal, which is a mild stylistic choice rather than a substantive error.
Dimension Breakdown
Only two sides appear in the visible text: the sponsoring drugmakers (cited as the source of results, not quoted directly) and one MD Anderson physician who is enthusiastic about the findings. No independent or sceptical researchers are quoted in the visible portion.
The language is largely plain and attributed ('according to results of a major study released Thursday by drugmakers'). The adjectives 'major', 'significantly' and 'first-of-its-kind' give a promotional tone, and the one evaluative quote ('a big one') is attributed to a named physician.
The one figure given is a relative reduction of 42% in the risk of recurrence at two years, with the study credited. No absolute risk, sample size or confidence interval appears in the visible text, so the number is presented without context that a reader would need to judge its size.
The visible text presents the study's sponsors and one supportive clinician. There are no visible voices on limitations, safety, alternative treatments or patient experience, even though a patient is pictured in the caption.
The headline ('helps reduce the chances of melanoma patients' tumors returning') is measured and consistent with the lede, which describes a reduction in recurrence risk when the vaccine is added to standard post-surgery treatment.
The story does not say how large or long the trial was, whether results have been peer reviewed or only released by the companies, how the 42% figure compares with absolute risk, or what safety findings were reported. These omissions limit a reader's ability to judge how much the result matters.
Missing Perspectives
- Independent researchers not connected to Moderna or Merck, who could assess the trial design, sample size and the meaning of the 42% relative reduction. This matters because the sponsors released the results.
- Safety and side effects. A treatment with a newly tailored vaccine raises questions a reader would want answered, and the visible text is silent on them.
- Trial participants. A patient is pictured in the caption, but the visible text does not quote any patient about their experience or the trade-offs.
- Cost, availability and regulatory status. The story does not say whether the vaccine is approved or how widely it would be accessible, which affects how readers should interpret the news.
Highlighted Passages
“according to results of a major study released Thursday by drugmakers”
“The field has been looking for a win and I think this one is a big one”
“A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back”
Key Facts
- According to the article, results of the study were released Thursday, October 22, 2026, by the drugmakers Moderna and Merck.
- According to the article, the vaccine is custom-made for each patient to match that patient's tumour.
- According to the article, adding the vaccine to standard post-surgery treatment reduced the risk of melanoma returning two years after surgery by 42%, based on what the article calls the most advanced study to date of this strategy.
- Dr. Hussein Tawbi of MD Anderson Cancer Center says 'the field has been looking for a win and I think this one is a big one.'
- The article describes the vaccine as a first-of-its-kind cancer vaccine, and the photo caption places the consultation at UT MD Anderson Cancer Center in Houston on October 19, 2026.
